Antonella Scala
@antonellascl95
Followers
606
Following
993
Media
22
Statuses
332
Cardiology Resident
Ferrara, Emilia Romagna
Joined January 2021
Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial ❤️💔 OPEN ACCESS🔓 and now with final PDF version 📰available in the European Heart Journal 👉 https://t.co/EvIT85z3dA
@ESC_Journals @escardio @ehj_ed #TCT2025 @crfheart
2
55
161
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial https://t.co/JzTjGMCjDG
@ehjopen @SaDeRosa78 @ProfMagnusBack @SABOURETcardio #EHJOpen
3
146
451
Just published Thanks and congratulations to all the co-authors @JEscaned @ziadalinyc @divaka_perera @AntonioMariaLe2 @sbrugaletta @PCRonline @crfheart @CircAHA @BernardBruyne @fredericbouisse @DamienCollison
1
18
44
So proud to present our work at #GISE2025 Thanks to @CircIntv for the publication! @SimoneBiscaglia @GianlucaCampo78 @sicigise
https://t.co/xm8XO35bnm
ahajournals.org
BACKGROUND: The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) showed the superiority of complete revascularization in older patients with...
0
4
11
Another 💊 from the #PIPELINE trial. Patients were stratified with #SPPB scale. Do you know that #SPPB showed a strongest association with mortality? Strongest than age, LVEF, renal function, etc
🚨 Just published in @NEJM: The PIpELINe Trial 🇮🇹 👵512 pts ≥65y, ↓ physical performance 1 mo after MI ⚖️ Multidomain rehab vs usual care ❤️ CV death/unplanned hosp: 12.6% vs 20.6% (HR 0.57, p=0.01) 💪Rehab works—also in frail elderly 🔗 https://t.co/55Es7090y0
#ESC2025
0
2
6
Some pills from the #PIpELINe trial... the exercise 🏃♀️ training 💪mixed few supervised sessions and 🏡 based exercises. The compliance was around 75%. 🔝as compared to previous studies
🚨 Just published in @NEJM: The PIpELINe Trial 🇮🇹 👵512 pts ≥65y, ↓ physical performance 1 mo after MI ⚖️ Multidomain rehab vs usual care ❤️ CV death/unplanned hosp: 12.6% vs 20.6% (HR 0.57, p=0.01) 💪Rehab works—also in frail elderly 🔗 https://t.co/55Es7090y0
#ESC2025
1
8
28
New #SevereAS updates with earlier AVR recommendations from @escardio #ESCcongress ☀️ Asymptomatic Severe AS: Earlier Intervention 🔴 NEW Class IIa-A recommendation: ➡️ Consider intervention in asymptomatic patients with severe, high-gradient AS and preserved LVEF ≥50%, if
🚨 Hot off the press! The 2025 #ESC #EACTS Guidelines for Valvular Heart Disease are here 🫀 ➡️ Patients are at the centre ➡️ 28 new recommendations ➡️ 50 revised recommendations 💡 The guidelines emphasize the role of the Expert Heart Valve Centre: 🏥 Institutional
3
33
84
Here we are!!! After @theFIREtrial the further step with the #PIpELINe trial
nejm.org
The benefit of rehabilitation interventions in patients who are 65 years of age or older with myocardial infarction and impaired physical performance remains unclear. In this multicenter, randomize...
0
11
37
The PIpELINe trial investigated the superiority of multidomain rehabilitation in older #MI patients with impaired physical performance | Physical Activity Intervention in ELderly Patients With Myocardial INfarction | https://t.co/8F811sJPlG
1
6
9
In this #SWEDEHEART registry analysis of #STEMI w/ multivessel disease, complete #revasc, whether angio or physiology-guided, was independently associated with better outcomes, including mortality. https://t.co/psA01ksCkh
#JACCINT #Revascularization #CardioX @ColinBerryMD
1
10
35
Coronary Atherosclerosis Phenotypes in Non-Flow-Limiting Nonculprit Lesions. Focal CAD lesions may be worse than diffuse disease patterns. Presented @PCRonline #EuroPCR and published simultaneously @EuroInterventio #AHAJournals #cardiotwitter @matser89
https://t.co/SW25WZHojR
0
19
51
Colchicine substantially reduces MACE including cardiovascular death, #cvMI and ischemic stroke compared with placebo in patients with vascular disease, according to two meta-analyses of randomized controlled trials. Read more: https://t.co/kMSOVyLRVc
#cvPrev #CardioX
acc.org
2
52
114
Our new publ from COAPT in Circ CV Interv: Elevated natriuretic peptides were a stronger risk factor for death and HF hosp than prior HF hosp within 1 yr, although prognosis was worst if both were present. MitraClip improved outcomes regardless of risk.
2
12
57
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events. read the results of the US Family Heart Database in #EHJ 👉 https://t.co/RIr1ahR4XU
@RoccoMontone @ehj_ed
0
27
93
Take a look to this comprehensive review on cardiac conduction disorders in young adults: very parctical, extremely useful and helpful in daily clincial practice! https://t.co/FzJFXxT8lU
@cristinaballa1 @Fra_Vitali90 @lucacanov
0
2
6
#CoronaryPhysiology
#MedEd LIVE CASE Ferrara Italy 🇮🇹 CT-guidance Anatomy + physiology 👋 @SimoneBiscaglia
@GianlucaCampo78 👨💻 Join VIRTUALLY via the OPTIMA app https://t.co/SLY3HimhxD… T H E PHYSIOLOGY COURSE ➡️ 28-29/04 Belgium🇧🇪 https://t.co/QrregKxdTp
0
5
12
This #JACCINT retrospective, multicenter, observational study suggests that #SGLT2i may slow the progression of non-severe aortic stenosis! Check out the full paper here: https://t.co/VLdqaHI6DA
#vhdAS
2
40
117
AZALEA–TIMI 71 RCT 🔬 Abelacimab vs rivaroxaban in #AFib at moderate-to-high risk of #stroke ✅ Primary endpoint: major or clinically relevant non-major bleeding ⚠️ Stroke prevention is still uncertain 🖇️ https://t.co/FzQueg2MEz
#ESCStroke @NEJM
0
7
28
I do not understand your concerns... all trials with the exception of one (FAVOR 3) are consistent, physio and ivus are better than angio and probably excluding very peculiar setting similar between them. Isn't easier to assume that the outlier is the FAVOR 3?
I don’t think the transitive property can be easily applied in interventional cardiology (or at least, a network meta-analysis would be needed), but if that were the case, then after the results of FLAVOUR II, I feel more confused than ever: iFR is noninferior to FFR for guiding
1
5
8
First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms,
4
104
235